Literature DB >> 1355550

Postoperative course of plasma protein binding of lignocaine, ropivacaine and bupivacaine in sheep.

A J Rutten1, L E Mather, J L Plummer, E C Henning.   

Abstract

The plasma protein binding of the 2,6-xylidide local anaesthetic agents lignocaine, ropivacaine and bupivacaine enantiomers was determined by equilibrium dialysis in plasma obtained from chronically catheterized sheep before and up to 21 days after surgery. Three concentrations (1, 5 and 10 mg L-1), were used for each agent. Concentration-dependent binding was evident for each agent throughout the study period. R(+)-Bupivacaine was more extensively bound than S(-)-bupivacaine at the higher concentrations. Compared with pre-surgery, binding of each agent was less on the first postoperative day but did not differ significantly from days 8 to 21.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355550     DOI: 10.1111/j.2042-7158.1992.tb03620.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

Review 1.  Analgesia for Sheep in Commercial Production: Where to Next?

Authors:  Alison Small; Andrew David Fisher; Caroline Lee; Ian Colditz
Journal:  Animals (Basel)       Date:  2021-04-14       Impact factor: 2.752

2.  Pharmacokinetics of bupivacaine enantiomers in sheep: influence of dosage regimen and study design.

Authors:  L E Mather; A J Rutten; J L Plummer
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

Review 3.  Recent advances in the pharmacokinetics of local anaesthetics. Long-acting amide enantiomers and continuous infusions.

Authors:  J M Thomas; S A Schug
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

4.  Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate.

Authors:  A G Burm; A D van der Meer; J W van Kleef; P W Zeijlmans; K Groen
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.